Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

Abstract

Altered pharmacokinetics of antibody drugs has been reported in advanced gastric cancer (AGC). We aim to evaluate bevacizumab pharmacokinetics in AGC from the Phase III trial (AVAGAST), and explore the influence of patient variables. Bevacizumab concentrations (Cp) were measured in plasma samples taken following disease progression from 162 patients (7.5 mg/kg every 3 weeks). Predicted Cp [median and 90% prediction interval] was simulated using the population pharmacokinetic model established for other cancers (PPK model) and compared to observed Cp. Bevacizumab clearance was estimated using NONMEM and compared between subgroups. Patient characteristics of AGC are similar to other cancers except for lower body weight despite higher percentage of males. Eighty-five percent of observed Cp was below the median predicted Cp and 38% below the lower boundary of the 90% prediction interval. Median bevacizumab clearance in AGC was 4.5 versus 3 mL/day/kg in other cancers. Bevacizumab clearance was significantly faster (p < 0.05) in patients without gastrectomy (n = 42) or lower albumin. Clearance appeared to be faster in patients with lower total protein, higher ECOG scores, more metastatic sites, and poorer response. No significant difference in bevacizumab concentrations and clearance was observed between Asian and Non-Asian patients. AGC patients exhibited significantly lower bevacizumab exposure due to an approximate 50% increase in clearance versus other cancers. Bevacizumab is cleared faster in patients without prior gastrectomy. No significant difference in bevacizumab pharmacokinetics was observed between Asian and Non-Asian patients. The underlying mechanism for faster bevacizumab clearance in AGC is unknown and warrants further research.Electronic supplementary materialThe online version of this article (doi:10.1208/s12248-014-9631-6) contains supplementary material, which is available to authorized users.

Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time‐Varying Clearance

“…Given the general nature of the time‐varying CL hypotheses, it would be expected that other monoclonal antibody therapies display this behavior. In fact, lower CL associated with improved health status has been reported for trastuzumab and bevacizumab …”

“…In fact, lower CL associated with improved health status has been reported for trastuzumab 20 and bevacizumab. 21,22 Time-varying CL as an early biomarker of tumor response in advanced metastatic disease…”

Inhibitory effects of bevacizumab monoclonal antibodies in combination with chemotherapy in different time sequences on a human gastric carcinoma cell line

“…Combining targeted therapy with chemotherapy has a synergistic effect. However, the best protocols for administering these two types of drugs have not been determined [8,9]. Therefore, this study was a preliminary exploratory study.…”

Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this?

“…In solid tumors, the clearance of bevacizumab in advanced gastric cancer was also found to be higher than in patients with less advanced disease. 9 Other cases in which mAb clearance is impacted by tumor burden have been reported, 4 suggesting similarly variable pharmacokinetics in mAbs use to treat a wide range of solid and hematologic tumors. In these studies, low mAb trough concentrations were associated with poor prognosis, supporting the potential for TDM as a tool to improve outcomes.…”